Subtype
Benign Skin Epithelial Neoplasm
CI-CAN-00000546Explore in graph →
Non-malignant10 active trials
- NCIt
- C7341
Loading cancer entity…
Subtype
CI-CAN-00000546Explore in graph →
Clinical trials
60 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05799157 | Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts | completed | Phase 2 | 153 | Veradermics, Inc.INDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT03487549 | Cantharidin and Occlusion in Verruca Epithelium(COVE-1) | completed | Phase 2 | 56 | Verrica Pharmaceuticals Inc.INDUSTRY | 1 | Nov 27, 2024 | clinicaltrials |
| NCT05896215 |
| OM202JP Clinical Study of KNP2002 |
| completed |
| Phase 2 |
| 159 |
| KinoPharma Inc.INDUSTRY |
| 1 |
| Sep 27, 2024 |
| clinicaltrials |
| NCT05877313 | Nitric Oxide Releasing Solution (NORS) For The Treatment Of Human Papillomavirus(HPV) Verrucae Plantaris (Plantar Warts) | completed | Phase 2 | 20 | Sanotize Research and Development corp.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT03210337 | A Phase2 of A-101 Topical Solution in Subjects With Common Warts | completed | Phase 2 | 157 | Aclaris Therapeutics, Inc.INDUSTRY | 1 | May 1, 2019 | clinicaltrials |
| NCT03278028 | A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts | completed | Phase 2 | 159 | Aclaris Therapeutics, Inc.INDUSTRY | 1 | Apr 9, 2019 | clinicaltrials |
| NCT02483455 | ALC-919 For The Treatment Of Common Warts | completed | Phase 2 | 21 | Veloce BioPharma LLCINDUSTRY | 1 | Mar 9, 2016 | clinicaltrials |
| NCT01214564 | Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis | completed | Phase 2 | 24 | PeplinINDUSTRY | 1 | Jan 25, 2011 | clinicaltrials |
Data updated 22 days agoSource updated May 8, 2025source: clinicaltrials